<DOC>
	<DOC>NCT02127476</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of KHK6640, given as a single dose and as multiple doses in patients with Prodromal Alzheimer's Disease (AD) or Mild to Moderate AD.</brief_summary>
	<brief_title>A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients with prodromal AD or mild to moderate AD Clinical Dementia Rating (CDR) score of 0.5, 1.0, or 2.0 Have a cognitive impairment Low AÎ² and high Tau in Cerebrospinal fluid (CSF) Mini Mental State Examination (MMSE) score &gt; 16 at Screening Previous active treatment with an AD immunotherapy in an investigational study Use of another investigational drug within 30 days of screening History or presence of clinically significant seizures, brain trauma, transient ischemic attack, and/or cerebrovascular disease Presence of a neurological condition that could be contributing to cognitive impairment above and beyond that caused by the subject's AD Evidence of infection, tumor, or other clinically significant lesions that could indicate a dementia diagnosis other than AD</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>